ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Louisville, KY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Triple Negative Breast Cancer
Breast Cancer

Ovarian Cancer trials near Louisville, KY, USA:

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004)

efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...

Enrolling
Fallopian Tube Cancer
Ovarian Cancer
Drug: ONC-392
Drug: Pembrolizumab

Phase 2

OncoC4

Louisville, Kentucky, United States and 20 other locations

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 176 other locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, wh...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

Phase 3

ImmunoGen
ImmunoGen

Louisville, Kentucky, United States and 207 other locations

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Placebo Oral Tablet
Drug: Rucaparib

Phase 3

pharmaand

Louisville, Kentucky, United States and 237 other locations

Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA)

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer...

Enrolling
Ovarian Cancer
Lung Adenocarcinoma
Drug: AZD5305
Drug: AZD5335

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Louisville, Kentucky, United States and 38 other locations

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected i...

Enrolling
Advanced Ovarian Carcinoma
Ovarian Neoplasms
Drug: NKT3447

Phase 1

NiKang Therapeutics

Louisville, Kentucky, United States and 6 other locations

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

The primary objective of this study is to evaluate progression-free survival (PFS) by blinded independent central review (BICR) in patients treated w...

Active, not recruiting
Ovarian Neoplasm
Fallopian Tube Neoplasms
Drug: Nab-paclitaxel 100 mg/m^2
Drug: Nab-paclitaxel 80 mg/m^2

Phase 3

Corcept Therapeutics
Corcept Therapeutics

Louisville, Kentucky, United States and 116 other locations

A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

2 study to evaluate the clinical activity, safety, and potentially predictive biomarker profile of ZN-c3 in subjects with High-Grade Serous Ovarian...

Active, not recruiting
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Drug: ZN-c3

Phase 2

K-Group Beta

Louisville, Kentucky, United States and 58 other locations

PF-07104091 as a Single Agent and in Combination Therapy

the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian...

Active, not recruiting
Breast Cancer
Small Cell Lung Cancer
Drug: PF-07104091 monotherapy dose expansion (ovarian)
Drug: PF-07104091 monotherapy dose expansion (SCLC)

Phase 1, Phase 2

Pfizer
Pfizer

Louisville, Kentucky, United States and 51 other locations

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced an...

Active, not recruiting
Bladder Cancer
Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Cyclophosphamide

Phase 2

Immunovaccine

Louisville, Kentucky, United States and 22 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems